Sam Brusco, Associate Editor08.23.22
Abbott has received U.S. Food and Drug Administration (FDA) approval for its next-gen Proclaim Plus spinal cord stimulation (SCS) system with proprietary FlexBurst360 therapy.
FlexBurst360 therapy is the newest generation of Abbott’s BurstBR stimulation, with pain coverage across up to six areas of the trunk and/or limbs. The therapy also allows programming to be adjusted as therapy needs evolve.
Proclaim Plus is recharge-free with a battery that can span up to 10 years at the lowest program setting (0.6mA). Therapy settings can be tuned using a personal mobile device or an Abbott-provided mobile device. This can be used to access the NeuroSphere Virtual Clinic, which lets patients communicate with physicians, ensure proper device functionality, and receive remote adjustments to therapy settings as needed.
"At Abbott, we are deeply committed to advancing the field of neurostimulation, thus helping people address the challenges they face while managing their chronic pain," Pedro Malha, Abbott’s VP of neuromodulation, told the press. "Our latest development, Proclaim Plus with FlexBurst360 therapy, is yet another testament of that commitment."
FlexBurst360 therapy is the newest generation of Abbott’s BurstBR stimulation, with pain coverage across up to six areas of the trunk and/or limbs. The therapy also allows programming to be adjusted as therapy needs evolve.
Proclaim Plus is recharge-free with a battery that can span up to 10 years at the lowest program setting (0.6mA). Therapy settings can be tuned using a personal mobile device or an Abbott-provided mobile device. This can be used to access the NeuroSphere Virtual Clinic, which lets patients communicate with physicians, ensure proper device functionality, and receive remote adjustments to therapy settings as needed.
"At Abbott, we are deeply committed to advancing the field of neurostimulation, thus helping people address the challenges they face while managing their chronic pain," Pedro Malha, Abbott’s VP of neuromodulation, told the press. "Our latest development, Proclaim Plus with FlexBurst360 therapy, is yet another testament of that commitment."